f5 Therapeutics
f5 Therapeutics was a San Diego biotech developing molecular-glue drugs with its NExMod platform. In March 2026 the company announced it was winding down, according to BioSpace.
The Story
f5 Therapeutics was a San Diego biotechnology company working on molecular-glue drugs developed with its NExMod platform. BioSpace reported that the platform used phenotypic screening to look for targets for conditions that are hard to treat with conventional drugs, and that the company said it had identified 11 potential targets.
In March 2026 the company announced it was winding down. BioSpace reported the company's LinkedIn announcement saying the past few years had been difficult for early-stage biotech, with funding for young platforms at multi-year lows, and that the team had "pushed as hard as we could, for as long as we could."
BioSpace reported that the company's LinkedIn page listed a company size of two to 10 employees. No public funding total was stated in that report.
Timeline
Funding
f5 Therapeutics's total funding is not stated in the sources below.
What Happened
Wound down (March 2026); the company said the funding environment for early-stage biotech platforms had been difficult